Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Rating of “Moderate Buy” from Analysts

Century Therapeutics, Inc. (NASDAQ:IPSC) has been assigned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $3.80.

Several research analysts have recently weighed in on the company. Piper Sandler boosted their target price on Century Therapeutics from $2.00 to $4.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Leerink Partners cut shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Century Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Century Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 6th. Finally, Wall Street Zen downgraded shares of Century Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday.

Insider Buying and Selling at Century Therapeutics

In other Century Therapeutics news, insider Chad Cowan acquired 58,060 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was purchased at an average cost of $0.85 per share, with a total value of $49,351.00. Following the transaction, the insider owned 1,045,087 shares of the company’s stock, valued at $888,323.95. This trade represents a 5.88% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Brent Pfeiffenberger acquired 52,000 shares of Century Therapeutics stock in a transaction that occurred on Friday, December 12th. The stock was bought at an average price of $0.58 per share, for a total transaction of $30,160.00. Following the completion of the acquisition, the chief executive officer owned 3,322,990 shares in the company, valued at $1,927,334.20. This trade represents a 1.59% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 145,060 shares of company stock valued at $97,011 and have sold 65,695 shares valued at $29,625. 4.37% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Prudential Financial Inc. purchased a new stake in shares of Century Therapeutics in the 2nd quarter valued at approximately $25,000. Bank of America Corp DE lifted its stake in Century Therapeutics by 109.1% during the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock worth $67,000 after purchasing an additional 34,466 shares in the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Century Therapeutics during the second quarter worth $38,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Century Therapeutics during the second quarter worth $50,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Century Therapeutics in the 2nd quarter valued at $51,000. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Century Therapeutics Stock Down 2.7%

Shares of IPSC opened at $1.79 on Thursday. Century Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.71. The stock has a market cap of $156.45 million, a PE ratio of -5.59 and a beta of 1.75. The firm’s fifty day moving average is $1.31 and its two-hundred day moving average is $0.81.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07. As a group, research analysts anticipate that Century Therapeutics will post -1.61 earnings per share for the current year.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.